REverSe TRanscrIptase chain termination (RESTRICT) for selective measurement of nucleotide analogs used in HIV care and prevention
Open Access
- 14 July 2022
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 8 (1) , e10369
Abstract
Sufficient drug concentrations are required for efficacy of antiretroviral drugs used in HIV care and prevention. Measurement of nucleotide analogs, included in most HIV medication regimens, enables monitoring of short‐ and long‐term adherence and the risk of treatment failure. The REverSe TRanscrIptase Chain Termination (RESTRICT) assay rapidly infers the concentration of intracellular nucleotide analogs based on the inhibition of DNA synthesis by HIV reverse transcriptase enzyme. Here, we introduce a probabilistic model for RESTRICT and demonstrate selective measurement of multiple nucleotide analogs using DNA templates designed according to the chemical structure of each drug. We measure clinically relevant concentrations of tenofovir diphosphate, emtricitabine triphosphate, lamivudine triphosphate, and azidothymidine triphosphate with agreement between experiment and theory. RESTRICT represents a new class of activity‐based assays for therapeutic drug monitoring in HIV care and could be extended to other diseases treated with nucleotide analogs.Keywords
All Related Versions
Funding Information
- Center for AIDS Research, University of Washington
- M.J. Murdock Charitable Trust
- Momental Foundation
- National Institute of Allergy and Infectious Diseases (R01AI136648, R01AI157756, R21AI127200)
- University of Washington
- M.J. Murdock Charitable Trust
- National Institute of Biomedical Imaging and Bioengineering (U54EB027690)
- National Institutes of Health (AI027757)
This publication has 54 references indexed in Scilit:
- Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseasesNature Reviews Drug Discovery, 2013
- Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug ExposureAIDS Research and Human Retroviruses, 2013
- Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogsMass Spectrometry Reviews, 2011
- Characterization of PicoGreen Interaction with dsDNA and the Origin of Its Fluorescence Enhancement upon BindingBiophysical Journal, 2010
- Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: A reviewJournal of Chromatography B, 2010
- Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adultsAIDS, 2007
- Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood CellsAntimicrobial Agents and Chemotherapy, 2007
- The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical ToxicitiesClinical Infectious Diseases, 2004
- Tenofovir Disoproxil FumarateClinical Pharmacokinetics, 2004
- HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasmaJournal of Medical Virology, 2003